Infographics

  1. Pandemic's Influence On Small Molecule API Outsourcing Risk Mitigation 6/14/2021

    ISR asked 121 outsourcers of small molecule API about how the pandemic has influenced risk mitigation strategies with regard to outsourcing. More than half said they plan to increase contingency planning.

  2. Small Molecule Drug Substance Outsourcing 5/12/2021

    In Q4 2020, ISR asked 123 outsourcers of small molecule API about the proportion of manufacturing allocated across three different approaches to outsourcing: tactical outsourcing, preferred providers, and strategic partnerships. The data show that the largest proportion of work is allocated tactically (38%), but that is expected to shift to preferred providers (41%) over the next three years as more outsourcers’ companies establish preferred relationships.

  3. Covid's Impact on Outsourced Small Molecule Manufacturing 4/16/2021

    In Q42020, ISR surveyed 249 sponsors who outsource small molecule manufacturing to learn if their company experienced outsourced manufacturing complications as a result of the Covid-19 pandemic. Small molecule drug substance outsourcers were slightly more likely to report complications than small molecule drug substance outsourcers, 45% vs 40%.

  4. Small Molecule Drug Substance Outsourcing Drivers By Company Size 3/16/2021

    In Q42020, ISR surveyed 123 sponsors who outsource small molecule drug substance manufacturing to learn more about their primary reason for outsourcing. The data show that sponsors from large pharma tend to use CMOs to augment internal manufacturing capacity (68%) while sponsors from non-large pharma use CMOs for all manufacturing needs (79%). 

  5. Customer Loyalty In Small Molecule API Manufacturing 1/15/2021

    In Q42020, ISR surveyed 123 sponsors who outsource small molecule API to gain insight into customer loyalty. CMO loyalty is computed as an index that consists of overall satisfaction, willingness to recommend, and the likelihood of using the contract manufacturer again. The data below show companies with ten or more responses from recent users and an industry average derived from all CMOs included in the research; their loyalty component scores are aggregated, averaged and then weighted based on the number of customer interactions.

  6. Reasons CDMOs Lose Oral Dose Manufacturing Bids 11/13/2020

    In Q2, 2019, ISR asked 101 respondents who outsource oral dose drug product manufacturing what is the main reason a CDMO may lose the bid for an outsourced manufacturing project. Regulatory violations / FDA form 483 warnings topped the list, capturing 30% of respondents’ votes.

  7. Reasons CDMOs Lose Sterile Injectable Manufacturing Bids 11/13/2020

    In Q2 2019, ISR asked 101 respondents who outsource sterile injectable drug product manufacturing what is the main reason a CDMO may lose the bid for an outsourced manufacturing project. Regulatory violations / FDA form 483 warnings topped the list, capturing 25% of respondents’ votes..

  8. Outsourcers' Opinions On CMO M&A Activity 9/15/2020

    In Q4, 2019, ISR asked 676 buyers of outsourced manufacturing services about their personal feelings regarding mergers and acquisitions in the contract manufacturing industry. One-third of respondents disagree-strongly disagree that M&A activity paves the way for better quality CMOs, while one-fifth of respondents agree-strongly agree. Nearly half neither agreed, nor disagreed that mergers and acquisitions impact the quality of contract manufacturers.

  9. Reasons CDMOs Lose Bioprocessing Bids 9/15/2020

    In Q2 2020, ISR asked 100 respondents who outsource bioprocessing what is the main reason a CDMO may lose the bid for an outsourced bioprocessing project. Regulatory violations / FDA form 483 warnings topped the list, capturing 32% of respondents’ votes.

  10. Small Molecule Drug Product Outsourcing 8/17/2020

    In Q4 2019, ISR asked 176 outsourcers of small molecule drug product manufacturing about the proportion of work allocated across three different approaches to outsourcing: tactical outsourcing, preferred providers, and strategic partnerships. The data show that the largest proportion of work (40%) is allocated to preferred providers, even though 43% of respondents work at companies that do not have preferred provider agreements.